近日，复星医药旗下复星万邦销售的复泽霖®利丙双卡因乳膏在阿里健康首发。该产品是一种外用表面 麻醉剂，适用于皮肤穿刺及浅层外科手术前的镇痛，已在全球范围内拥有长期应用历史。此次合作，标 志着复星医药进一步拓展院外市场，携手阿里健康共同为消费者提供更便捷、专业、合规的镇痛解决方 案。 作为国家药品监督管理局批准用于皮肤穿刺及浅层外科手术镇痛的处方药，利丙双卡因乳膏自1998年在 中国上市以来，一直是临床基础麻醉的重要选择。 然而，随着医美、男科等消费医疗场景的蓬勃发展，该产品在院外市场的应用也迅速显性化，在男科领 域，它被《早泄诊断与治疗指南》列为一线推荐方案；在蓬勃发展的轻医美市场(如光电项目、微针、 注射等)，它则成为术前镇痛的合规首选。 伴随政策规范的逐步完善与用户需求的日益凸显，复星医药积极推动该产品走向更广阔的市场。此次选 择与阿里健康合作，正是基于作为"新特药首发阵地"在数字化健康服务方面的平台优势，旨在更直接地 触达注重隐私、便捷与安全的消费者。 近年来，利丙双卡因乳膏在公立医院及消费医疗市场均呈现稳步增长。根据微信公众号邴药说的测算， 利丙双卡因乳膏国内市场持续向上增长，2024年利丙双卡因乳膏在 ...

Summary of Conference Call on Healthcare Services and Pharmacy Sector Industry Overview - The focus is on the healthcare services and pharmacy sectors within the pharmaceutical industry, particularly consumer-oriented segments, which are currently viewed positively due to historical low valuations after a prolonged adjustment period [1][2]. Key Points and Arguments Healthcare Services - The healthcare services sector has experienced significant declines, with current valuations at historical lows, indicating a potential for recovery by 2026 [1]. - Specific companies highlighted for their optimistic 2026 guidance include Tongce Medical, Gushengtang, and Aier Eye Hospital, all expected to show double-digit growth [1][2]. - The recovery in the sector is anticipated to be driven by improvements in supply structure and consumer environment, leading to a business rebound [2]. - Aier Eye Hospital is introducing new consumer-oriented surgical procedures, which may increase average transaction values despite stable surgical volumes [2]. Market Trends - Data from October 2025 shows positive growth in outpatient services in cities like Chongqing and Tianjin, with increases of 5-6% and 13-14% respectively [3]. - The overall trend indicates a recovery in both service volume and pricing, particularly in consumer-oriented medical fields like ophthalmology [3][4]. AI Integration - AI is expected to empower healthcare service companies, with applications like Ant Group's AI health app showing significant user growth, indicating a new growth driver for leading healthcare service firms [4][5]. Pharmacy Sector - The pharmacy sector is experiencing notable improvements in performance since Q3 2025, with leading companies showing consistent same-store sales growth [6]. - The sector is supported by government policies aimed at increasing industry concentration and chain store rates, which are expected to drive medium-term performance [6][7]. - Companies like Yifeng Pharmacy and Dazhong Pharmacy are highlighted for their strong cash flow and dividend yields, with Dazhong reporting a 60% dividend payout ratio [6][7]. Online vs. Offline Dynamics - The online pharmacy market is growing rapidly, but it serves a different demographic compared to traditional pharmacies, which cater more to older consumers [7][8]. - The online pharmacy market is projected to grow significantly, driven by products like GLP-1, but the overall growth rate may stabilize as both online and offline markets adjust [9][10]. Regulatory Environment - Recent government policies emphasize enhancing pharmacy service capabilities and supporting prescription outsourcing, which could lead to increased revenue opportunities for pharmacies [13][14]. - The focus on compliance and competition is expected to benefit larger pharmacy chains with established networks and resources for mergers and acquisitions [17]. Home Medical Devices - The home medical device sector is poised for growth due to an aging population and increasing health awareness, with significant potential in health monitoring devices like blood pressure monitors and glucose meters [18][19]. - Companies such as Yuyue Medical and Sanofi are recommended for their strong growth prospects in this segment [21]. Conclusion - The healthcare services, pharmacy, and home medical device sectors are expected to experience a bottom reversal, driven by improving fundamentals and supportive government policies. Key players in these sectors are well-positioned to capitalize on these trends, making them attractive investment opportunities moving forward [1][21].

Market Overview - The Hang Seng Index closed down by 1.82% at 26,590.32, with a decline of 491.59 points and a trading volume of 251 billion [2] - The Hang Seng Tech Index fell by 2.13% to 5,270.70, decreasing by 114.65 points with a trading volume of 68.9 billion [2] - The Hang Seng Biotech Index dropped by 3.34% to 15,654.19, down by 541.42 points with a trading volume of 11 billion [2] - The Hang Seng China Enterprises Index decreased by 2.06% to 9,007.86, down by 189.52 points with a trading volume of 90 billion [2] - The Hang Seng Composite Index fell by 1.69% to 4,078.66, down by 70.08 points with a trading volume of 178.1 billion [2] Sector Performance - Technology stocks experienced widespread declines, with notable drops including SenseTime and Tencent Music falling over 5%, Meituan and Kingsoft down over 4%, and Ctrip and Tencent Holdings down over 3% [2] - Other major tech companies such as Kuaishou, Alibaba, Baidu, SMIC, Xiaomi, and JD Health all saw declines exceeding 2% [2] Individual Stock Movements - Kingdee International saw a significant drop of 7.77% to 9.970, with a trading volume of 721 million [3] - SenseTime fell by 5.78% to 2.610, with a trading volume of 2.326 billion [3] - Tencent Music decreased by 5.62% to 57.100, with a trading volume of 170 million [3] - Meituan dropped by 4.24% to 81.400, with a trading volume of 5.524 billion [3] - Kingsoft fell by 4.23% to 26.740, with a trading volume of 424 million [3] - Ctrip Group decreased by 3.83% to 406.800, with a trading volume of 2.044 billion [3] - Tencent Holdings fell by 3.35% to 520.000, with a trading volume of 18.829 billion [3] - Other notable declines included Alibaba Health down 2.94%, Kuaishou down 2.77%, Alibaba down 2.76%, SMIC down 2.39%, Xiaomi down 2.24%, and JD Health down 2.15% [3] Robotics Sector - The robotics sector collectively weakened, with UBTECH falling over 8%, Sanhua Intelligent Control down over 6%, and Horizon Robotics down 2% [5][6]

Group 1 - Major tech stocks in Hong Kong experienced a significant decline, with Tencent Music dropping over 5%, Kingsoft and Meituan falling over 4%, and Ctrip Group nearing a 4% drop [1] - The Hang Seng Index opened lower and continued to decline, with a current drop of 2.12%, while the Hang Seng Tech Index fell by 2.39% [2] Group 2 - Specific stock performance includes: - Kingdee International at 9.820, down 0.990, a decrease of 9.16% - SenseTime at 2.590, down 0.180, a decrease of 6.50% - Tencent Music at 57.100, down 3.400, a decrease of 5.62% - Kingsoft at 26.600, down 1.320, a decrease of 4.73% - Meituan at 81.150, down 3.850, a decrease of 4.53% - Ctrip Group at 406.200, down 16.800, a decrease of 3.97% - Alibaba Health at 5.880, down 0.240, a decrease of 3.92% - Kuaishou at 66.000, down 2.550, a decrease of 3.72% - Tencent Holdings at 518.000, down 20.000, a decrease of 3.72% - JD Health at 56.250, down 1.900, a decrease of 3.27% - Alibaba at 147.300, down 4.900, a decrease of 3.22% - Baidu Group at 129.200, down 4.000, a decrease of 3.00% - Xiaomi Group at 35.540, down 1.020, a decrease of 2.79% - Bilibili at 228.200, down 6.600, a decrease of 2.81% [3]

Market Overview - The market opened higher on February 24, with all three major indices rising over 1%: Shanghai Composite Index increased by 1.17%, Shenzhen Component Index by 1.82%, and ChiNext Index by 1.76% [1] - Over 4,200 stocks in the market experienced gains, with sectors such as non-ferrous metals, oil and gas, optical fiber, and chemicals leading the increases [1] Sector Performance - Oil and gas stocks surged, with companies like Zhun Oil Co., Shandong Molong, Intercontinental Oil & Gas, and Zhongman Petroleum hitting the daily limit [2] - The chemical sector saw significant growth, with Meibang Co. achieving four consecutive trading limit increases, and Jinniu Chemical recording four limits in seven days [2] - The glass fiber concept remained active, with International Composites rising over 4% and achieving a historical high [2] Geopolitical Impact - The escalation of tensions between the U.S. and Iran during the A-share market's holiday period heightened concerns over potential disruptions in oil supply, contributing to price increases in non-ferrous and chemical products [2] - Precious metals also saw a rise, with Hunan Silver hitting the daily limit and several other gold-related stocks following suit. During the holiday period, global precious metal prices fluctuated, with gold rising over 7% and silver nearly 20% from February 18 to February 23 [2] Declines in Specific Sectors - The film and cinema sector faced a collective downturn, with companies like Hengdian Film, Bona Film, and China Film hitting the daily limit down [2][3][4] - Notable declines included Light Media down 18.99%, Happiness Blue Sea down 17.04%, and Bona Film down 10.02% [3][4] Hong Kong Market Performance - The Hong Kong market experienced a decline, with the Hang Seng Index falling by 1.93% and the Hang Seng Technology Index by 2.36%. Major companies like Meituan, Baidu, Tencent, and Alibaba also saw significant drops [5][6] - The total trading volume in the Hong Kong market was 138.68 billion, with net outflows of 1.22 billion from southbound funds [5]

免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 个股表现上，恒基地产、万州国际、中国石油股份领涨恒指成分股；泡泡玛特、瀚森制药、阿里健康领 跌恒指成分股。万州国际盘中还创出历史新高。 恒生科技指数表现更弱，开盘报5330.26点，下跌1.02%，盘中持续走低，截至9时38分，报5255.02点， 跌幅扩大至2.42%。 板块表现上，大多数板块下跌，其中信息科技、软件服务板块领跌；石油天然气板块逆势上涨。 今日（2月24日），港股开盘后呈现震荡走弱态势，受隔夜美股大幅回调拖累，主要股指集体低开，随 后持续下探，市场呈现结构性分化格局。截至9时38分，恒生指数与恒生科技指数均出现明显下跌，部 分板块逆势异动，个股表现分化显著。 指数方面，恒生指数开盘报26913.68点，下跌0.62%，随后震荡下行，截至9时38分，报26682.85点，跌 幅扩大至1.47%。 ...

Core Viewpoint - Southbound funds have increased their holdings in Alibaba Health (00241.HK) significantly, indicating growing investor confidence in the company [1] Group 1: Investment Activity - On February 23, southbound funds increased their holdings by 6.5 million shares of Alibaba Health [1] - Over the past 5 trading days, there have been 4 days of net increases in holdings, totaling 20.14 million shares [1] - In the last 20 trading days, there were 14 days of net increases, amounting to 20.54 million shares [1] - Currently, southbound funds hold 1.985 billion shares of Alibaba Health, representing 12.27% of the company's total issued ordinary shares [1] Group 2: Company Overview - Alibaba Health Information Technology Co., Ltd. provides industrial internet solutions for the medical and pharmaceutical industry [1] - The company is the flagship platform of Alibaba Group in the health sector, focusing on the development of pharmaceutical health product sales [1] - It operates a pharmaceutical e-commerce platform and consumer healthcare service platform, utilizing cloud computing and big data for traceability and digital healthcare [1]

Group 1 - The mainland internet healthcare sector is entering a new phase driven by tech giants accelerating AI innovation and government policy support, such as the online initial diagnosis pilot program launched in Beijing [1] - Despite challenges in profitability, leading companies are leveraging AI ecosystems and innovative strategies for long-term sustainable growth [1] Group 2 - The company maintains a "Buy" rating for Alibaba Health (00241) with a target price of HKD 7.8, expecting a compound annual growth rate (CAGR) of 13% in revenue and 24% in adjusted net profit from FY2026 to FY2028, driven by growth in innovative drugs and healthcare products, deepening synergy with Alibaba Group (09988), and increasing AI application [1] - The company also favors Ping An Good Doctor (01833) with a "Buy" rating and a target price of HKD 20, anticipating a CAGR of 16% in revenue and 56% in adjusted net profit from FY2025 to FY2027, supported by deepening synergy with Ping An Insurance (02318) and ongoing AI empowerment [1] Group 3 - The company maintains an "Overweight" rating for the mainland healthcare sector, preferring leading innovative pharmaceutical companies and contract research, development, and manufacturing organizations (CRDMOs) [2] - The company is optimistic about internet healthcare firms that effectively utilize real-world data to optimize AI algorithms and enhance service quality [2] - Preferred stocks include BeiGene (06160), Innovent Biologics (01801), Hansoh Pharmaceutical (03692), China Biologic Products (01177), Hutchison China MediTech (00013), WuXi Biologics (02269), WuXi AppTec (02359), and Alibaba Health [2]

Group 1 - The mainland internet healthcare sector is entering a new phase driven by tech giants accelerating AI innovation and government policy support, such as the online initial diagnosis pilot program launched in Beijing [1] - Despite challenges in profitability, leading companies are leveraging AI ecosystems and innovative strategies for long-term sustainable growth [1] - Alibaba Health (00241) is favored with a "Buy" rating and a target price of HKD 7.8, with expected revenue and adjusted net profit CAGR of 13% and 24% from FY2026 to FY2028, driven by innovative drugs, healthcare product growth, and deepening synergies with Alibaba [1] Group 2 - Ping An Good Doctor (01833) is also favored with a "Buy" rating and a target price of HKD 20, with expected revenue and adjusted net profit CAGR of 16% and 56% from FY2025 to FY2027, supported by synergies with Ping An (02318) and ongoing AI empowerment [1] - The firm maintains an "Overweight" rating on the mainland healthcare sector, preferring leading innovative pharmaceutical companies and contract research, development, and manufacturing organizations (CRDMOs) [2] - Companies that effectively utilize real-world data to optimize AI algorithms and enhance service quality in internet healthcare are also favored, with preferred stocks including BeiGene (06160), Innovent Biologics (01801), Hansoh Pharmaceutical (03692), China Biologic Products (01177), Hutchison China MediTech (00013), WuXi Biologics (02269), WuXi AppTec (02359), and Alibaba Health [2]

Group 1: Industry Insights - The growth of online pharmaceutical sales is driven by the penetration of original research drugs and the outflow of prescriptions, with foreign companies increasing their presence in outpatient settings for innovative drugs [1] - Major pharmaceutical e-commerce and internet healthcare platforms are enhancing their product and service offerings around original research drugs, leading to a rapid increase in market share for medical e-commerce [1] - The long-term potential for online pharmacies is significant due to policy-driven factors such as online insurance and prescription outflow, highlighting the cost-effectiveness and convenience of online pharmacies [1] Group 2: Company Performance - Alibaba Health's self-operated revenue is accelerating, with self-operated business accounting for nearly 90% of total revenue, driven by the trend of original research drugs [2] - The number of self-operated SKUs increased by 99% year-on-year to 1.61 million, with revenue growing by 19% year-on-year to 14.38 billion yuan as of FY26H1 [2] - Alibaba Health is the largest online B2C healthcare retail platform in terms of annual GMV and has revised the upper limit of its advertising service framework agreement, which will significantly contribute to profitability [1][2] Group 3: Future Opportunities - The integration of AI in health management presents new opportunities for Alibaba Health, with the potential to enhance sales through the "Qianwen Super Agent" and related applications [2] - The company is exploring serious medical applications and has launched the medical AI assistant "Hydrogen Ion" App, which may lead to commercialization through partnerships with pharmaceutical companies [2] Group 4: Financial Projections - Revenue forecasts for Alibaba Health are projected at 34.594 billion yuan and 38.235 billion yuan for the fiscal years 26 and 27, respectively, with adjusted net profits expected to be 2.499 billion yuan and 3.026 billion yuan [2] - The pharmaceutical e-commerce business is assigned a 3X PS for FY26, while the healthcare and digital services business is assigned a 6X PS, leading to a target value of 7.39 HKD per share and a "Buy" rating [2]